Cardiff Oncology used the biggest stage in oncology to take a real step forward. At the 2026 ASCO Annual Meeting on June 2, in a rapid oral session, the company presented updated data from CRDF-004, its randomized Phase 2 trial of onvansertib combined with standard-of-care chemotherapy regimens in first-line RAS-mutated metastatic colorectal cancer. The data showed that adding onvansertib to FOLFIRI and bevacizumab produced dose-dependent improvements in overall response rate and progression-free survival compared with standard of care alone.
Just as important as the data was the decision that followed it. Cardiff selected a 30mg onvansertib dose with FOLFIRI and bevacizumab for a planned Phase 3 trial designed to support potential accelerated approval based on objective response rate and full approval based on progression-free survival. Choosing a dose and a registrational design is the moment a program stops being an interesting signal and becomes an actual path to a drug.
Why RAS-mutated colorectal cancer matters
RAS-mutated colorectal cancer is a large, hard-to-treat population where front-line options have not changed dramatically in years, so a therapy that improves response and delays progression on top of standard chemotherapy addresses a genuine unmet need. The accelerated-approval design, using objective response rate as the basis for an earlier decision, is the kind of regulatory path that can shorten the distance to market if the Phase 3 delivers. Onvansertib is also being explored in pancreatic cancer, small cell lung cancer, and other tumors through investigator-initiated studies, which gives the platform optionality beyond the lead indication.
The other side
The honest caveats are the ones that apply to every single-asset oncology microcap. Phase 2 improvements, even dose-dependent ones, do not guarantee a Phase 3 win, and colorectal cancer trials are large, long, and expensive. Cardiff is clinical-stage with no product revenue and a cash runway the company has guided into the first quarter of 2027, which means financing the pivotal program is its own hurdle and dilution is a realistic part of getting there. The value is concentrated in a single trial reading out years from now.
- Registrational path set. Dose selected and a Phase 3 designed for potential accelerated approval on ORR.
- Real unmet need. First-line RAS-mutated colorectal cancer is a large population with few new options.
- Phase 2 is not Phase 3. Dose-dependent improvements still have to replicate in a large pivotal trial.
- Funding the pivotal. Runway into 1Q27 and no revenue mean financing the Phase 3 is a live risk.
What to watch
The formal start and design confirmation of the Phase 3, any FDA feedback on the accelerated-approval path, and how Cardiff funds the trial. The program has a dose and a plan. Now it needs the pivotal data and the money to generate it.
Disclosure
This article is independent editorial content and reflects the author's opinion and analysis as of the date of publication. It is not investment advice and should not be relied on as the basis for any investment decision. MicroCap Desk and its contributors received no compensation of any kind — cash, securities, or otherwise — from any company mentioned, or from any third party, in connection with this article. The author holds no position in any security mentioned. Information is drawn from sources believed reliable but is not guaranteed accurate or complete. Microcap securities carry a high risk of loss. Do your own research. See our full Disclosure.
